Megan Munsie elected to ISSCR Board of Directors

Professor Megan Munsie

Professor Megan Munsie was elected to the 2023 International Society for Stem Cell Research (ISSCR) Board of Directors, for a three-year term.

Founded in 2002, the ISSCR is an independent, global, nonprofit organization that promotes excellence in stem cell science and applications to human health.

Professor Munsie brings her extensive experience in public policy, community and professional education and advocacy for stem cell and related research to this role.

Munsie is the reNEW PREPARE theme lead, an interdisciplinary research team with expertise in medical sociology, science and technology studies, science communication, bioethics, clinical translation regulation, and health economics. PREPARE works with reNEW researchers to consider issues affecting potential impact, development, and delivery of socially robust stem cell medicine to the market.

Munsie is also the group leader of Stem Cell Ethics & Policy at Murdoch Children’s Research Institute, and the Professor of Emerging Technology (Stem Cells) at University of Melbourne. Her research focuses on understanding community attitudes and expectations in regenerative medicine and other emerging technologies. She also examines the role of policy and professional standards in enabling responsible translation.

She currently serves on two ISSCR Committees: Ethics, and Public Policy and is also the President of the Australasian Society for Stem Cell Research.

“I am so honoured to be recognised and selected by my peers and colleagues for this role. I look forward to serving the global stem cell community and supporting the ISSCR’s ongoing quest to promote excellence in stem cell science,” said Munsie.

You can read more in the ISSCR President Dr Amander T. Clark’s inaugural address.

reNEW secures access to new drug screening resources

All reNEW nodes now have access to large compound libraries for drug screening and drug development research. This access has been secured through reNEW membership of Compounds Australia and will help identifying potential therapeutic compounds through the stem cell-based disease models within reNEW.